hrcak mascot   Srce   HID

Libri Oncologici : Croatian Journal of Oncology, Vol.45 No.2-3 Prosinac 2017.

Pregledni rad

Advances in melanoma immunotherapy

Nina Dabelić ; Department of Oncology and Radiotherapy, Reff eral Center for Melanoma of Ministry of Health of Republic of Croatia, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Jasmina Marić Brozić ; Department of Oncology and Radiotherapy, Reff eral Center for Melanoma of Ministry of Health of Republic of Croatia, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Nikola Đaković ; Department of Oncology and Radiotherapy, Reff eral Center for Melanoma of Ministry of Health of Republic of Croatia, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Ante Bolanča ; Department of Oncology and Radiotherapy, Reff eral Center for Melanoma of Ministry of Health of Republic of Croatia, Sestre milosrdnice University Hospital Center, Zagreb, Croatia

Puni tekst: engleski, pdf (173 KB) str. 46-51 preuzimanja: 68* citiraj
APA 6th Edition
Dabelić, N., Marić Brozić, J., Đaković, N. i Bolanča, A. (2017). Advances in melanoma immunotherapy. Libri Oncologici, 45 (2-3), 46-51. Preuzeto s https://hrcak.srce.hr/192125
MLA 8th Edition
Dabelić, Nina, et al. "Advances in melanoma immunotherapy." Libri Oncologici, vol. 45, br. 2-3, 2017, str. 46-51. https://hrcak.srce.hr/192125. Citirano 21.06.2018.
Chicago 17th Edition
Dabelić, Nina, Jasmina Marić Brozić, Nikola Đaković i Ante Bolanča. "Advances in melanoma immunotherapy." Libri Oncologici 45, br. 2-3 (2017): 46-51. https://hrcak.srce.hr/192125

Sažetak
Melanoma is considered to be the most immunogenic malignant tumour. This fact is recognized for many years, and certain forms of immunotherapy have been used in melanoma therapy for a considerable time.
Treatment options for patients with metastatic melanoma have changed dramatically in the past 5 years, with the FDA approval of eight new therapeutic agents (immunotherapies and targeted therapies). During this period, melanoma immunotherapy has transitioned from cytokine-based treatment to antibody-mediated blockade of the cytotoxic Tlymphocyteassociated antigen4 (CTLA4) and, recently, the programmed cell-death protein 1 (PD1) immune checkpoints. These changes in the treatment options have dramatically improved patient outcomes, with the median overall survival of patients with metastatic melanoma increasing from approximately 9 months before 2011 to at least 2 years, and probably longer.
Various types of immunotherapy, like pembrolizumab, nivolumab, ipilimumab, combined therapy with nivolumab and ipilimumab, and T-VEC, have been established in recent years as the standard-of-care treatment for metastatic melanoma patients.

Ključne riječi
immunotherapy; melanoma; checkpoint inhibitors; oncolytic vaccines

Hrčak ID: 192125

URI
https://hrcak.srce.hr/192125

[hrvatski]

Posjeta: 100 *